In the intergroup analysis of variance of FbgC (Clauss method), P=0

In the intergroup analysis of variance of FbgC (Clauss method), P=0.044. C organizations (P=0.009); while the remaining 14 coagulation guidelines were not significantly different among the organizations. Although the levels of FbgC and FVIII:C in the FFP were reduced following treatment, this would not affect the medical effect of the FFP. Keywords:leukocyte filtration, irradiation, fresh freezing plasma, coagulation system, coagulation element == Intro == Fresh freezing plasma (FFP) is an alternate therapy mainly used in the treatment of clinical bleeding, which happens due to the deficiency of solitary and multiple coagulation factors induced by numerous causes. Leukocytes are a nontherapeutic component of FFP, which act as a kind of pollutant and increase the risk of adverse transfusion reactions when carrying out allogeneic transfusion. Currently, HOE 32020 the main method used to obvious the plasma of HOE 32020 residual leukocytes is definitely leukocyte filtration. Removal of leukocytes by this method HOE 32020 can significantly reduce adverse transfusion reactions; however, a certain quantity of leukocytes remain in the FFP, and some of these have the ability to proliferate (1,2). The leukocyte filtration method used only cannot sufficiently prevent the event of transfusion-associated graft-versus-host disease (TA-GVHD) (2,3). Although instances of FFP-infusion-induced TA-GVHD are rare there have been some reported instances in which, following filtration 106108lymphocytes remain in the FFP, and these remaining lymphocytes could cause TA-GVHD when used by individuals with immune function problems or suppression, or by individuals who BMP13 have undergone bone marrow transplantation (4). This study investigated the coagulation factors that remained in FFP following leukocyte removal and irradiation, with the aim of determining which coagulation factors were affected, as well as the degree of the effect. This info may be useful in improving the security and performance of medical transfusions. == Materials and methods == == Materials == Thirty hand bags of FFP, with 50 ml in each bag, were collected from 30 healthy donors by Luzhou city blood standard bank (Luzhou, China). Disposable FTS-RC202 (2200) leukocyte filtration-transfusion products was from Nanjing Shuangwei Biotechnology Co., Ltd. (Nanjing, China). This study was carried out in accordance with the Declaration of Helsinki. and with authorization from your Ethics Committee of Luzhou Medical College (Luzhou, China). Written educated consent was from all participants. == Experimental process == == Leukocyte filtration of FFP == The 30 hand bags of FFP, with 50 ml in each bag, were stored at 20C. The experiment was carried out five HOE 32020 instances. Six hand bags of FFP were taken out from your refrigerator, and after thawing inside a freezing plasma thawing package, each bag of FFP was processed using the disposable leukocyte filter and the filtered FFP was equally divided into two hand bags. The original bag retained 5 ml unfiltered FFP and was designated as the control (the A group). For the two hand bags of filtered FFP, one was designated the B group (leukocyte removal group), and the additional was subjected to irradiation, and designated the C group (leukocyte removal + irradiation group). == Plasma irradiation of the C group: == A blood irradiation instrument (Gammacell 1000; MDS Nordion, Ottawa, Canada) was used, having a radiation dose of 30 Gy and irradiation time of 11 min and 50 sec. == Detection of coagulation signals == A CA7000 automated blood coagulation analyzer (Sysmex Corporation, Kobe, Japan) was used to analyze the samples, and the following coagulation factors were tested: prothrombin time (PT; solidification method, Thromborel S Reagent); triggered partial thromboplastin time (APTT; solidification method, Dade Actin triggered Cephaloplastin Reagent); fibrinogen (FbgC; Dade Thrombin Reagent); thrombin time (TT; solidification method, Test Thrombin Reagent); D-dimer (D-Di; immunoturbidimetry); endogenous coagulation factors VIII, IV and VI (FVIII:C, FIV:C and FVI:C; solidification method, coagulation Element VIII, IV and VI Deficient Plasma); antithrombin III (AT III; chromogenic substrate method, Berichrom Antithrombin III); and exogenous coagulation factors FII:C, FVII:C, FX:C (solidification method, Coagulation Element II, VII and X Deficient Plasma). The above reagents were manufactured by Siemens (Marburg, Germany). The fibrin/fibrinogen degradation products (FDPs) were analyzed using the Nanopia P-FDP kit (Sekisui Medical Co., Ltd., Tokyo, Japan). Sample screening was managed purely in accordance with the instructions of the tools and reagents. Quality control screening was firstly performed, followed by sample testing. Following a testing, the results were recorded for analysis. == Statistical analysis == All data were subjected to statistical analysis with SPSS version 17.0 statistical software (SPSS, Inc., Chicago, IL, USA), and the results.